Importantly, treatment with Mito-Tempo, a mitochondrial-targeted ROS scavenger, mitigates DSS-induced colitis and upregulates NIX expression, further emphasizing the therapeutic potential of targeting mitochondrial ROS. Here, BNIP3L is linked to colitis.